All Stories

  1. Clozapine, suicide prevention and risk perception in psychiatry
  2. Reply to: “Pulmonary Embolism During Clozapine and Olanzapine Treatment: An Underrecognized Clinical Risk Highlighted by Pharmacovigilance Data”
  3. Emotional Blunting During Antidepressant Treatment: Implications for Clinical Decision‐Making and Patient‐Centred Care
  4. Informing Your Future Clozapine Patients of the Mortality Risk: Fear of Agranulocytosis vs. Pharmacovigilance Fatal Outcomes
  5. Integrating pharmacovigilance, pharmacokinetics and clinical outcomes in clozapine safety science
  6. A Systematic Review and a VigiBase Study of Accidental Clozapine Intoxications in Children and Adolescents
  7. Reply to “Beyond Hypersalivation: Protecting Older Clozapine Users through Better Recognition of Swallowing Vulnerability”
  8. VigiBase suggests that the number of deaths by suicide in adolescents with schizophrenia as a result of not taking clozapine may be much higher than the number of deaths from agranulocytosis after taking clozapine
  9. When Doing Nothing Feels Safer: A Multilevel Framework for Therapeutic Inertia in Psychiatry
  10. Comparative Pharmacovigilance Analysis of Pulmonary Embolism Across Antipsychotics in VigiBase
  11. Prescribing Under Uncertainty: The Hidden Psychology of Psychiatric Decision-Making
  12. When Doing Nothing Feels Safer: Therapeutic Inertia and Risk Perception in Psychiatry
  13. Reviewer recommendations and editorial outcomes in peer review: a longitudinal analysis of agreement and disagreement across review rounds
  14. Reply to beyond fatality signals: reconsidering clozapine safety through severe gastrointestinal hypomotility and real-world clinical complexity
  15. Changing Your Perspective on Fatal Outcomes in Clozapine-treated patients.
  16. Psychiatry Between Ethics and Activism: Rethinking Professional Authority and Scientific Integrity in Contemporary Mental Healthcare
  17. Autonomy Under Uncertainty: Are We Overestimating Decision-Making Capacity in Psychiatric End-of-Life Contexts?
  18. Beyond Consensus, Beyond Closure: Rethinking Relapse in Schizophrenia Through a Multidimensional Lens
  19. Beyond Symptom Thresholds: Toward a Clinically and Culturally Inclusive Definition of Relapse in Schizophrenia
  20. Digital Adverse Events: Rethinking Psychopathology and Public Mental Health in the Era of Human–AI Interaction
  21. Reclaiming Pharmacovigilance: Bridging the Evidence–Practice Gap in Psychopharmacology
  22. Co-Created Digital Pretherapy Psychoeducation for Outpatients in Specialized Mental Health Care: Usability Evaluation and Patient Satisfaction Study
  23. A Study in VigiBase of Clozapine Fatal Outcomes in 7,874 Middle-Aged versus 4,380 Young Adults
  24. A Comparative Analysis of Fatal Outcomes in 5,370 Geriatric Versus 12,254 Nongeriatric Adult Patients: A Clozapine Study in VigiBase
  25. Psychiatry is not the science of unhappiness
  26. Insomnio: enfoque clínico y terapéutico
  27. Clozapine and Suicide in VigiBase
  28. Fatal Outcomes in Use of Clozapine
  29. The Crisis of Meaning in Aging and the Expansion of Medically Unjustified Euthanasia: A Psychiatric Imperative
  30. Letter to the Editor regarding: “Towards a name change of schizophrenia: positive and negative symptoms disorder (PND)”
  31. On dosing equity, scientific responsibility, and what remains unsaid
  32. Clozapine and Regulatory Inertia: Revisiting Evidence, Risks, and Reform
  33. Co-Created Digital Pretherapy Psychoeducation for Outpatients in Specialized Mental Health Care: Usability Evaluation and Patient Satisfaction Study (Preprint)
  34. Clozapine-treated patients and myocardial infarction in adults: a pharmacovigilance study in VigiBase interpreted in the context of the literature
  35. Perceived Stress and Clinical Insomnia in Primary Care: Associations with Lifestyle and Medication Use
  36. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I
  37. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II
  38. The Sleep Expectation–Reality Gap: Exploring Discrepancies Between Perceived and Ideal Sleep Duration in Primary Care Patients
  39. Reflections on the Potential and Risks of AI for Scientific Article Writing after the AI Endorsement by Some Scientific Publishers: Focusing on Scopus AI
  40. Clozapine pharmacovigilance in Croatia: underreporting of specific adverse drug reactions and excellent reporting of suicide attempts
  41. The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force
  42. A case of recurrent priapism during prolonged clozapine administration
  43. Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data
  44. Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety
  45. Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature
  46. Exploring the Relationship Between Psychological Constructs and Decision-Making Preferences in Psychiatric Outpatients
  47. Implications of psychological reactance for clinical practice in psychiatry including a systematic review.
  48. Investigating in VigiBase® over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia
  49. Psychoeducational group interventions for adults diagnosed with attention-deficit/ hyperactivity disorder: a scoping review of feasibility, acceptability, and outcome measures
  50. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK
  51. Clozapine-associated pericarditis and pancreatitis in children and adolescents: A systematic literature review and pharmacovigilance study using the VigiBase database
  52. An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance
  53. Will ChatGPT3 Substitute for us as Clozapine Experts?
  54. Guía internacional Para una dosificación más Segura de la clozapina en adultos mediante el uso de 6 titulaciones personalizadas de dosis basados en la etnicidad, la Proteína C Reactiva y los niveles de clozapina
  55. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance
  56. Psychiatric Patients’ Perceived Health Control and Reactance: Implications for Medication Adherence
  57. Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients
  58. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)
  59. Escaping the Long Shadow Cast by Agranulocytosis
  60. Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in VigiBase
  61. NURSING STUDENT’S VIEWS ON THE DUTY OF CARE: A CROSS-SECTIONAL STUDY IN TWO COUNTRIES
  62. Clozapine-induced myocarditis in children and adolescents: a pharmacovigilance study using VigiBase and a systematic literature review
  63. Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: Focus on reports from various countries
  64. Clozapine-induced myocarditis in Russia: Animal studies but no clinical studies
  65. Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase
  66. Telepsychiatry: The future is already present
  67. Psychometric Properties of the WHO-5 Well-Being Index among Nurses during the COVID-19 Pandemic: A Cross-Sectional Study in Three Countries
  68. Clozapine and the risk of haematological malignancies
  69. An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine
  70. Evaluating the Effect of a Telepsychiatry Educational Program on the Awareness, Knowledge, Attitude, and Skills of Telepsychiatry Among Spanish Psychiatrists during COVID-19 Pandemic
  71. An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s
  72. The duty to care and nurses' well-being during a pandemic
  73. Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase
  74. Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
  75. Promoting safer clozapine dosing in the Americas
  76. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
  77. The Mediating Role of Resilience in the Relationship between Perceived Stress and Mental Health
  78. Miocarditis inducida por la clozapina: estudios animales pero no clínicos
  79. Clozapine-associated myocarditis in the World Health Organization’s pharmacovigilance database: Focus on reports from various countries
  80. Clinimetric Criteria for Patient-Reported Outcome Measures
  81. Exploring patterns in psychiatric outpatients’ preferences for involvement in decision-making: a latent class analysis approach
  82. Effect of necessity‐concern framework and polypharmacy on treatment adherence in psychiatric patients. Comparing an Argentinian with a Spanish sample
  83. An update on the complex relationship between clozapine and pneumonia
  84. Effects of a peer co-facilitated educational programme for parents of children with ADHD: a feasibility randomised controlled trial protocol
  85. Self-Report for Measuring and Predicting Medication Adherence: Experts’ Experience in Predicting Adherence in Stable Psychiatric Outpatients and in Pharmacokinetics
  86. Patient-reported well-being: psychometric properties of the world health organization well-being index in specialised community mental health settings
  87. Assessment of shared decision-making in community mental health care: Validation of the CollaboRATE
  88. Psychometric properties of the Five‐item World Health Organization Well‐being Index used in mental health services: Protocol for a systematic review
  89. The association of clozapine and haematological malignancies needs to be replicated by other studies and more importantly by analyses of subsamples from VigiBase
  90. A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology
  91. Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics
  92. The necessity‐concern framework in the assessment of treatment adherence of psychiatric patients and the role of polypharmacy in a Spanish sample
  93. Data From the World Health Organization’s Pharmacovigilance Database Supports the Prominent Role of Pneumonia in Mortality Associated With Clozapine Adverse Drug Reactions
  94. Development and validation of the Patient’s Health Belief Questionnaire on Psychiatric Treatment
  95. Effectiveness and cost-effectiveness of a multicomponent intervention to improve medication adherence in people with depressive disorders - MAPDep: a study protocol for a cluster randomized controlled trial
  96. Ethnopsychopharmacology study of patients' beliefs regarding concerns about and necessity of taking psychiatric medications
  97. A Clinimetric Approach for Improving the Measurement of Pharmacophobia with Replication in Two Other Samples
  98. Meet Our Editorial Board Member
  99. Predictive validity of the Sidorkiewicz instrument in Spanish: Assessing individual drug adherence in psychiatric patients
  100. Skepticism and pharmacophobia toward medication may negatively impact adherence to psychiatric medications: a comparison among outpatient samples recruited in Spain, Argentina, and Venezuela
  101. Burnout y reactividad al estrés
  102. The Art of Pharmacotherapy
  103. Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approach
  104. Reviving Research on Medication Attitudes for Improving Pharmacotherapy: Focusing on Adherence
  105. Are Acceptance and Skepticism Determinant Factors for Adherence to Drug Treatment in Psychiatric Patients?
  106. Validity of the Control Preferences Scale in patients with emotional disorders
  107. Perceived Health Control
  108. Treatment-related decisional conflict in patients with depressive and anxious disorders
  109. The effect of a brief educational programme added to mental health treatment to improve patient activation: A randomized controlled trial in community mental health centres
  110. Preferencias por las decisiones compartidas en pacientes con depresión
  111. Métodos de valoración de la adherencia al tratamiento psiquiátrico en la práctica clínica
  112. Validation of the General Self-Efficacy Scale in psychiatric outpatient care
  113. Coste-utilidad de asenapina frente a olanzapina para el tratamiento de los episodios maniacos de pacientes con trastorno bipolar tipo I
  114. Explaining pharmacophobia and pharmacophilia in psychiatric patients: relationship with treatment adherence
  115. Psychometric properties of the eight-item Morisky Medication Adherence Scale (MMAS-8) in a psychiatric outpatient setting
  116. What Do Psychiatric Patients Believe Regarding Where Control Over Their Illness Lies?
  117. The relationship of psychological reactance, health locus of control and sense of self-efficacy with adherence to treatment in psychiatric outpatients with depression
  118. To what extent is treatment adherence of psychiatric patients influenced by their participation in shared decision making?
  119. Psychological reactance in psychiatric patients: Examining the dimensionality and correlates of the Hong Psychological Reactance Scale in a large clinical sample
  120. Psychiatric patients’ preferences and experiences in clinical decision-making: Examining concordance and correlates of patients’ preferences
  121. Validation of the Spanish version of the 9-item Shared Decision-Making Questionnaire
  122. Preferences for participation in shared decision making of psychiatric outpatients with affective disorders
  123. To what extent psychiatric patients feel involved in decision making about their mental health care? Relationships with socio-demographic, clinical, and psychological variables
  124. Risk factors for non-adherence to antidepressant treatment in patients with mood disorders
  125. Shared decision making in psychiatric practice and the primary care setting is unique, as measured using a 9-item Shared Decision Making Questionnaire (SDM-Q-9)
  126. Sociodemographic and clinical predictors of compliance with antidepressants for depressive disorders: systematic review of observational studies
  127. Psychiatric outpatients' self-reported adherence versus psychiatrists' impressions on adherence in affective disorders
  128. Estrategias de manejo de los antidepresivos desde la perspectiva de los pacientes: luchando interna y externamente
  129. Attitudes toward concordance in psychiatry: a comparative, cross-sectional study of psychiatric patients and mental health professionals
  130. Psychiatric patients’ attitudes towards concordance and shared decision making
  131. Mental health professionals' attitudes to partnership in medicine taking: a validation study of the Leeds Attitude to Concordance Scale II
  132. ¿Están relacionadas la obesidad y otras comorbilidades físicas con la enfermedad mental?
  133. Editorial [Hot Topic: Compliance, Adherence and Concordance in Medicine Taking of Psychiatric Patients (Guest Editor: Carlos De las Cuevas)]
  134. Towards a Clarification of Terminology in Medicine Taking Behavior: Compliance, Adherence and Concordance are Related Although Different Terms with Different Uses
  135. Adaptation and validation study of the Beliefs about Medicines Questionnaire in psychiatric outpatients in a community mental health setting
  136. Antidepressant Use in Early Pregnancy
  137. Lithium Use During Early, Late Pregnancy, and Breastfeeding
  138. Psychomotor performance and fitness to drive: The influence of psychiatric disease and its pharmacological treatment
  139. The relationship among Mental Health Status (GHQ-12), Health Related Quality of Life (EQ-5D) and Health-State Utilities in a general population
  140. Versión española consensuada de la Severity of Dependence Scale (SDS)
  141. Fitness to Drive of Psychiatric Patients
  142. Attitudes toward psychiatric drug treatment: the experience of being treated
  143. Duloxetine-Induced Excessive Disturbing and Disabling Yawning
  144. Are psychotropics drugs used in pregnancy?
  145. Randomized Clinical Trial of Telepsychiatry through Videoconference versus Face-to-Face Conventional Psychiatric Treatment
  146. Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy
  147. Polypsychopharmacy
  148. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis
  149. Telepsychiatry: Psychiatric consultation through videoconference patients' perception and satisfaction
  150. Telepsychiatry: Psychiatric consultation through videoconference clinical results
  151. Polypharmacy in psychiatric practice in the Canary Islands
  152. Do therapeutic indications of antidepressants change from one year to another?
  153. Evaluación cualitativa en teledermatología: resultados del proyecto piloto Telemedicina 2000
  154. Telepsychiatry in the Canary Islands: user acceptance and satisfaction
  155. Telepsiquiatría: utopía o realidad asistencial
  156. Benzodiazepines: more "behavioural" addiction than dependence
  157. Burnout en los profesionales de la atención a las drogodependencias
  158. Telepsiquiatría: utopía o realidad asistencial
  159. Variations in antidepressant prescribing practice: clinical need or market influences?
  160. The Severity of Dependence Scale (SDS) as screening test for benzodiazepine dependence: SDS validation study
  161. Benzodiazepine prescription is different in the public and private sectors
  162. Prescribed daily doses and ‘risk factors’ associated with the use of benzodiazepines in primary care
  163. Benzodiazepine audit in primary care
  164. PSYCHOPATHOLOGICAL PROFILE IN ANXIETY DISORDERS
  165. INSOMNIA AND AFFECTIVE DISORDERS